Discoverybiomed, Inc.

Birmingham, AL 35242

SBIR Award Summary

Total Number of Awards 21
Total Value of Awards $7.88MM
First Award Date 09/25/08
Most Recent Award Date 09/30/17

Key Personnel

Last Name Name Awards Contact
Schwiebert Erik Mills Schwiebert 17
Seales Eric Clinton Seales 2
Streiff John H Streiff 6
Watnick Terry J Watnick 3
MAI DEBORAH MAI 4

21 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/30/17 - 03/31/18

Principal Investigators for Small Business: DiscoveryBioMed, Inc. (DBM) Project Summary Abstract The over-arching goal of this proposed SBIR-driven program is to create relevant DiscoveryBioMed (DBM) human cellular toxicity (HCT) platforms for the kidney grown in 3D and in 2D cell culture formats for a new ?gold standard? in lead therapeutic ass...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-052
Budget: 05/05/17 - 04/30/18

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/15/16 - 04/30/17

? DESCRIPTION (provided by applicant): DiscoveryBioMed, Inc. (DBM) completed recently Phase I SBIR-funded goals, milestones, specific experimental aims and efforts to screen 58,000 synthetic organic small molecules on immortalized and primary differentiated human adipocyte platforms and to validate the high-throughput screening (HTS)-based Dr...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 05/01/16 - 04/30/17

? DESCRIPTION (provided by applicant): DiscoveryBioMed, Inc. (DBM) completed recently Phase I SBIR-funded goals, milestones, specific experimental aims and efforts to screen 58,000 synthetic organic small molecules on immortalized and primary differentiated human adipocyte platforms and to validate the high-throughput screening (HTS)-based Dru...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-052
Budget: 04/01/16 - 03/31/17

? DESCRIPTION (provided by applicant): DiscoveryBioMed, Inc. (DBM, Inc. or DBM) specializes in normal and diseased human cell platform engineering. DBM has assembled a consortium of experts; whereby, collectively, we seek Fast Track SBIR funding to establish and offer a Product Line Menu of normal and ADPKD human cell platforms for the academ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/01/15 - 06/30/16

DESCRIPTION (provided by applicant): An important discovery and validation event occurred recently within human cell-based drug discovery programs at DiscoveryBioMed, Inc. (DBM), yielding a lead class of cytostatic anti-proliferative small molecules that display nanomolar potency and marked efficacy against hyperproliferative human PKD cells th...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 05/01/15 - 04/30/16

DESCRIPTION (provided by applicant): DiscoveryBioMed, Inc. (DBM) completed recently Phase I SBIR-funded goals, milestones, specific experimental aims and efforts to screen 58,000 synthetic organic small molecules on immortalized and primary differentiated human adipocyte platforms and to validate the high-throughput screening (HTS)-based Drug Di...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/01/14 - 06/30/15

DESCRIPTION (provided by applicant): An important discovery and validation event occurred recently within human cell-based drug discovery programs at DiscoveryBioMed, Inc. (DBM), yielding a lead class of cytostatic anti-proliferative small molecules that display nanomolar potency and marked efficacy against hyperproliferative human PKD cells th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 06/01/14 - 05/31/15

Project Summary Abstract DiscoveryBioMed, Inc. (DBM) has launched an innovative and automation-friendly drug discovery program to screen a collection of small molecular compounds on a human epithelial cell platform expressing physiologically relevant levels of the wild-type Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) to discover a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/15/13 - 09/14/14

DESCRIPTION (provided by applicant): DiscoveryBioMed, Inc. (DBM) has launched an innovative and automation-friendly drug discovery program to screen synthetic organic small molecule collections on differentiated human adipocyte platforms to discover a new class of therapeutic drugs for type 2 diabetes mellitus (T2DM) and obesity. Differentiated ...

Load More